Looks like the results were not unambiguous (not a slam dunk as market would have anticipated) so a deeper analysis is required. While there may be questions in people’s minds about whether it will make it to the therapeutic market IMO just the prophylactic market itself is huge and can be a source of recurring revenue in the order of $100’s of millions annually. This alone would make our MC much higher but ST thinkers or those don’t understand it correctly may prefer to stay away given the wider phase 2 and phase 3 that may need to happen.
Will be interesting to hear the webinar. I also found it interesting that they had a quote from the chairman and a SAB member.
AIMO. DYOR
ILA Price at posting:
17.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)